Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of SIM0718 in Healthy Adults
NCT06701149Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rademikibart in atopic dermatitis (AD) (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Nov 2024; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06701149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701149.